Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.46 |
| ▸ | PRKDC | P78527 | 4/20 | 0.46 |
| ▸ | TNKS | O95271 | 4/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.42 |
| ▸ | PARG | Q86W56 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949875 | 0.88 | TNKS (0.51) | TNKSTNKS2PARGMAPTTP53 | |
| SCHEMBL11960885 | 0.86 | TNKS (0.46) | PIK3CAPRKDCTNKSTNKS2PARG | |
| SCHEMBL16181499 | 0.84 | TNKS (0.46) | PIK3CAPRKDCTNKSTNKS2PARG | |
| SCHEMBL11961007 | 0.83 | ALDH1A1 (0.48) | PIK3CAPRKDCTNKSTNKS2MAPT | |
| SCHEMBL11961802 | 0.83 | RECQL (0.46) | PIK3CAPRKDCPARGMAPT | |
| SCHEMBL11961335 | 0.82 | PARG (0.43) | PIK3CAPRKDCPARGMAPTTP53 | |
| SCHEMBL11960991 | 0.82 | MAPT (0.42) | PIK3CAPRKDCTNKSTNKS2PARG | |
| SCHEMBL11960898 | 0.81 | MTNR1A (0.50) | PARGMAPTTP53 | |
| SCHEMBL11960896 | 0.81 | TP53 (0.43) | PIK3CAPRKDCTNKSTNKS2PARG | |
| SCHEMBL11961753 | 0.81 | MAPT (0.44) | PIK3CAPRKDCPARGMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865704-B2 | Wnt pathway antagonists | SIENA BIOTECH S.P.A. (IT) | 2014-10-21 | — | — | US | disclosed |
| US-20120196851-A1 | WNT PATHWAY ANTAGONISTS | SIENA BIOTECH S.P.A. (IT) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196851-A1 | WNT PATHWAY ANTAGONISTS | WNT1, WNT3A, CTNNB1 | PIK3CA 1566/4885PRKDC 3453/4885TNKS 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.